Eosinophilic Granulomatosis With Polyangiitis: Newer Therapies

Eosinophilic Granulomatosis With Polyangiitis: Newer Therapies

Purpose of review Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic disseminated vasculitis associated with extravascular granulomas in patients suffering from asthma and tissue eosinophilia. Current therapies to achieve remission and prevent relapse include glucocorticoids and immu...

Full description

Saved in:
Bibliographic Details
Published in:Current rheumatology reports Vol. 20; no. 5; p. 23
Main Authors: Navarro-Mendoza, Erika P., Tobón, Gabriel J.
Format: Journal Article
Language:English
Published: New York Springer US 01-05-2018
Subjects:
Medicine
Medicine & Public Health
Rheumatology
Section Editor
Topical Collection on Vasculitis
Vasculitis (L Espinoza
Rituximab
Omalizumab
Mepolizumab
Churg−Strauss syndrome
Therapeutics
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose of review Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic disseminated vasculitis associated with extravascular granulomas in patients suffering from asthma and tissue eosinophilia. Current therapies to achieve remission and prevent relapse include glucocorticoids and immunosuppressants like cyclophosphamide. Recent findings With the right treatment, clinical prognosis is favorable, so concerted efforts have been made in recent years to find new alternatives for treating severe EGPA. Monoclonal antibodies such as omalizumab, rituximab, and mepolizumab are among these new options. Summary This review summarizes the pathogenesis and clinical manifestations of EGPA and critically examines current and emerging therapies.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1523-3774
1534-6307
DOI:10.1007/s11926-018-0736-2